Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib

Cancer Letters
Ratnakar PattiC Damodar Reddy

Abstract

In this study the role of cyclooxygenase-2 (COX-2) in primitive neuroectodermal tumor (PNET) the most malignant brain tumors of childhood was investigated. COX-2 expression in human brain tumor biopsy samples (seven/seven) was about 6-8-fold higher than normal brain tissue and several PNET cell lines also express COX-2. The effect of selective COX-2 inhibitors, celecoxib and rofecoxib on the growth of two PNET cell lines (DAOY and PFSK) was determined. Celecoxib was more potent than rofecoxib in suppressing cell growth. Growth inhibition by celecoxib and rofecoxib was independent of Bcl-2 expression. Celecoxib suppressed the expression of Akt and activated the caspase-3 in DAOY and PFSK, whereas rofecoxib did not have such an effect.

References

Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J A MitchellJ R Vane
May 6, 1993·The New England Journal of Medicine·F M GiardielloG J Offerhaus
Dec 27, 1996·The Journal of Biological Chemistry·W L SmithD L DeWitt
Jan 5, 2001·Expert Opinion on Investigational Drugs·A T KokiJ L Masferrer
Jul 27, 2001·Journal of Cancer Research and Clinical Oncology·W DempkeH J Schmoll

❮ Previous
Next ❯

Citations

Jul 3, 2007·International Ophthalmology·Pinar C OzdalMiguel N Burnier
Apr 25, 2003·Biochemical and Biophysical Research Communications·Madhava C ReddyP Reddanna
Nov 26, 2002·Cancer Letters·Bolleddula JayaprakasamMuraleedharan G Nair
Jun 8, 2006·Journal of the National Cancer Institute·Sabine GröschGerd Geisslinger
Apr 15, 2004·Experimental Neurology·Gabriele SchillingDavid R Borchelt
Dec 18, 2007·Free Radical Biology & Medicine·Jung-A ChoiJae-Hong Kim
Apr 2, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Zichen ZhangAlphonse E Sirica
Aug 9, 2003·The Journal of Pharmacy and Pharmacology·Naveen AhujaBhupinder Singh
Oct 19, 2016·Drug Discovery Today·Jiange QiuJianxiong Jiang
Oct 19, 2004·Oncogene·Min-Hyuk YooJae-Hong Kim
Oct 14, 2003·Regional Anesthesia and Pain Medicine·Noor M Gajraj
Jun 9, 2006·Expert Review of Anticancer Therapy·Mark Luttjeboer, Gertjan J L Kaspers
Oct 1, 2005·Journal of Neuro-oncology·Mark W Kieran
Jan 17, 2012·Oncotarget·John Inge JohnsenCecilia Söderberg-Nauclér
Aug 18, 2017·Clinical and Experimental Pharmacology & Physiology·Atsushi MatsuyamaHiroshi Takeuchi
May 23, 2003·Anesthesia and Analgesia·Noor M Gajraj
Jul 8, 2020·Pharmacological Reports : PR·J S Dileep KumarAkiva Mintz
Feb 24, 2011·Natural Product Reports·Li-Xia ChenFeng Qiu
Oct 1, 2005·Revista clínica española·J J Grau de Castro
Aug 6, 2021·Journal of Medicinal Chemistry·Madison N SluterJianxiong Jiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.